


## Life Settlement Assets PLC – Ordinary Share A

### Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

### Estimated Performance



### Commentary

#### Investment Terms

1.5% Management Fee

Researchers analyzed cohort life expectancy trends for people born between 1939 and 2000 across 23 high-income, low-mortality countries using multiple mortality forecasting models and found consistent evidence that the historic steady gains in longevity seen in the early 20th century have slowed markedly. Unlike earlier cohorts whose life expectancy increased almost linearly—largely due to dramatic reductions in infant and child mortality—the projected increases for later-born cohorts are significantly smaller, with no group born in this period expected to reach an average lifespan of 100 years. This deceleration is primarily driven by diminished mortality improvements at young ages, and even optimistic scenarios of enhanced adult survival are unlikely to recreate the rapid longevity growth of the past, highlighting implications for public health planning and expectations around aging and longevity.

#### Estimated NAV (USD)

99 189 358







#### NAV/Share

2.2470

The Share Class is reporting a performance of -0.67% for the month of October. Five HIV maturities were registered, contributing a total Death Benefit of \$0.45M; no maturity was registered in the non-HIV segment this month.

Number Of Policies	Net Death Benefits (USD)	Matured Policies YTD	Maturities YTD (USD)
3 695	381 808 235	89	19 179 415


Trust Investment Manager	Acheron Capital Ltd.	Company Secretary	ISCA Administration Services Limited
Administrator	Compagnie Européenne de Révision	ISIN Ticker	GB00BF1Q4B05 LSAA
Auditor	BDO UK LLP	Info	life@acheroncapital.com +44 207 258 5990



(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.


(2)Distribution by issue dates reflects the time since the life insurance policy was issued.

Source of Data: Acheron Capital Ltd unless otherwise stated.



### Maturities October 2025

Number of policies matured in October 2025	5
Corresponding number of insured	5
Total death benefit in October 2025 (US\$)	451 982
Valuation of Matured policies (US\$)	133 486



### Premiums Situation (US\$)<sup>(1)</sup>

Servicers Premiums Projection for the next 12 months	\$ 11.5M
Mortality Adjusted Premiums Projection for the next 12 months	\$ 11.0M
Estimated COI Net of Mortality for the next 12 months	\$ 10.5M

Top 10 Coverage				
Insured	Face (millions)	Total Face (millions)	Age (ALB)	Expiration Age*
1	2.0/1.0/1.0/0.9/0.3	5.2	97	100/100/120/110/120
2	3.0	3.0	69	90
3	2.8	2.8	94	100
4	2.0	2.0	105	120
5	1.2	1.2	64	100
	0.1/0.1/0.059/0.35/0.15/0.			100/100/100/95/95/100/95/
6	1/0.06/0.1/0.1	1.2	71	100/100
7	0.5/0.7	1.2	62	100/100
8	1.2	1.2	99/97	102/100 (survivorship))
9	1.0	1.0	68	95
10	1.0	1.0	62	75

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

\*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite 1, 7th Floor 50 Broadway, London, United Kingdom, SW1H 0BL.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.